EWTX News
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500PR NewswireBOULDER, Colo., Sept. 22, 2026 - TheMoA that...
PR Newswire
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500PR NewswireBOULDER, Colo., Sept. 22, 2026 - TheMoA that...
PR Newswire
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.
Zacks
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
Zacks
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER, Colo., Sept. 2, 2026 BOULDER, Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...
PR Newswire
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.
Zacks
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 PR Newswire BOULDER, Colo...
PR Newswire
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results Edgewise Therapeutics Reports Second Quarter 2026 Financial Results PR Newswire BOULDER, Colo., Aug. 6, 2026 Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive...
PR Newswire
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.
Zacks
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on...
PR Newswire
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business PR Newswire SURESNES, France, July 13, 2026 Acquisition supportsServier'sstrategicambition in rare neurologywithsevasemten...
PR Newswire